BioInvent International
8.12.2021 08:21:38 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV)
- BioInvent's pipeline expanding to four drug candidates in five clinical trials
Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial Application (CTA) for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
BI-1607 targets FcyRIIB but is modified in its Fc region to alter its affinity for Fc receptors. By selectively blocking FcyRIIB, BI-1607 enhances the activity of other therapeutic monoclonal antibodies, whose mechanism-of-action involves depletion of tumors or immune suppressive cells. Understanding the biology of FcR/Fc interactions was essential for generating BI-1607, which has a clearly differentiated profile from BioInvent's lead drug candidate BI-1206.
BioInvent intends to explore the activity of BI-1607 in advanced solid tumors and antibody combinations supported by strong preclinical data.
"We are pleased to have completed this step in the development. BI-1607 is a very promising approach given its ability to enhance anti-cancer immunity and approval of the CTA will expand the BioInvent pipeline to four drug candidates in five clinical trials, further underlining the productivity of our technology platform," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. In addition to BI-1607, the company has three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/676499/BioInvent-has-Submitted-a-CTA-for-a-Phase-12a-trial-of-BI-1607-a-Novel-anti-FcyRIIB-Antibody-for-the-Treatment-of-Patients-with-Solid-Tumors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fidelity Investments Upgrades FINOS Membership to Platinum, Reinforcing Its Strategic Commitment to Open Source Collaboration in Financial Services11.2.2026 15:00:00 CET | Press release
Following its leadership in launching Fluxnova, Fidelity's appointment to the FINOS Governing Board underscores the growing recognition of the ROI of open source for all market participants NEW YORK CITY, NY / ACCESS Newswire / February 11, 2026 / The Fintech Open Source Foundation (FINOS), the foundation of open innovation in financial services, today announced that Fidelity Investments has upgraded its FINOS membership to Platinum, reflecting Fidelity's deepening strategic commitment to open source collaboration, industry interoperability, and the responsible adoption of emerging technologies such as AI across regulated financial services. The membership upgrade builds directly on Fidelity's role in the formation of Fluxnova, a FINOS-hosted open source orchestration platform created to address critical industry needs around workflow automation, vendor independence, and long-term infrastructure sustainability. Fidelity spearheaded the project's contribution into FINOS, helping establi
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program10.2.2026 21:00:00 CET | Press release
GA-ASI's YFQ-42A Platform to Support Next-Generation Expeditionary Air Operations SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 10, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was competitively selected by the U.S. Marine Corps (USMC) for evaluation in the Marine Air-Ground Task Force Uncrewed Expeditionary Tactical Aircraft (MUX TACAIR) Collaborative Combat Aircraft (CCA) program. The agreement integrates GA-ASI's expertise in autonomy and uncrewed aircraft systems with a government-provided mission package, usingthe YFQ-42A platform as a surrogate to evaluate integration with crewed fighters. The contract initiates integration of a Marine Corps mission kit into the YFQ-42A surrogate platform for assessment within the Marine Air Ground Task Force (MAGTF). The USMC contract includes the rapid development of autonomy for the government-supplied mission kit - a cost-effective, sensor-rich, software-defined suite capable of delivering kinetic and non-kinetic effects -
Changing Your Dog's Diet May Help the Planet More Than Changing Your Own, Study Finds10.2.2026 17:30:00 CET | Press release
LONDON, UK / ACCESS Newswire / February 10, 2026 / Diets high in meat, eggs, and dairy products incur significant environmental costs. But a new study has revealed that, in many cases, switching your dog to a more sustainable diet may have a bigger impact on the planet and farmed animals than changing your own diet. The research, published in the journal Animals by veterinary Professor Andrew Knight, found that the average dog consumes around 13 farmed land animals annually within its diet, compared with nine for the average person--a difference of roughly 40%. This gap exists largely because a greater proportion of a typical dog's dietary energy comes from animal-based ingredients--about 34%--compared to around 19% for people. These figures represent global averages and vary by country. In high-income nations such as the United States, consumption is higher across the board. There, an average person consumes 24 farmed land animals annually, compared with 20 for a dog--a smaller differ
Reco Raises $30M B Round for a Total of $85M to Meet Rapidly Growing Demand for AI SaaS Security Among Enterprises10.2.2026 16:30:00 CET | Press release
After growing ARR by 400% in 2025, Reco secures new backing months after its last funding to secure AI SaaS usage NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2026 / Reco, a leader in securing AI SaaS environments, today announced a $30 million Series B funding round led by Zeev Ventures, with participation from all existing investors including Insight Partners, boldstart ventures, while adding new corporate investors Workday Ventures, TIAA Ventures, S Ventures, and Quadrille Capital. The new funding comes less than 10 months after Reco's previous raise to meet the exponential demand to discover and secure AI SaaS at any modern enterprise. The round follows another year of exceptional growth for Reco. After growing 500% year-over-year in 2024, the company scaled an additional 400% in 2025 on a significantly larger base, driven by a sharp increase in enterprise AI adoption and the rapid rise of shadow AI, where 71% of knowledge workers now use AI tools without IT approval an
Logista Strator and Shekel Sign an Agreement to Bring Innovendi Elite to Spain - The Autonomous Sales Solution That Boosts Sales10.2.2026 14:05:00 CET | Press release
The goal is to put a technology in the hands of tobacconists and the Spanish retail sector to open new revenue channels. MADRID, ES / ACCESS Newswire / February 10, 2026 / Logista Strator, the technology platform specialized in retail management and part of Logista, has reached a strategic agreement with Shekel, developer of WeightAI™ technology and manufacturer of Innovendi Elite, for its distribution in Spain and Portugal. The companies will present the Innovendi Elite at the Hospitality Innovation Planet (HIP) trade fair in Madrid from February 16-18, 2026. Innovendi Elite is a next-generation smart fridge that redefines the future of vending experience: an advanced autonomous retail solution that combines patented weighing technology with artificial intelligence to deliver a completely frictionless shopping experience. Customers pay by card or app, open the cooler, select their products, and continue on their way without waiting. Its ability to operate in continuous mode and adapt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom